Maintane 500 Injection contains Hydroxyprogesterone 500mg, a synthetic progestogen used primarily for its potent progestational activity. This medication is indicated for the prevention of preterm birth in pregnant women with a history of spontaneous preterm delivery. Hydroxyprogesterone functions by modulating the hormonal environment necessary to maintain pregnancy, thereby reducing uterine contractions and cervical changes associated with early labor. Administered via intramuscular injection, Maintane 500 provides sustained release of the active compound, ensuring prolonged therapeutic effects. It is essential that this injection is given under medical supervision, with dosing typically initiated between 16 and 20 weeks of gestation and continued until 37 weeks or delivery. Contraindications include known hypersensitivity to hydroxyprogesterone or its components, active thrombophlebitis, thromboembolic disorders, liver dysfunction, and undiagnosed vaginal bleeding. Common adverse effects may include injection site reactions, fluid retention, and mild gastrointestinal disturbances. Caution is advised in patients with a history of cardiovascular disease or diabetes. Maintane 500 Injection should be used in accordance with established clinical guidelines, ensuring careful monitoring of maternal and fetal health throughout the treatment course to optimize outcomes and minimize risks.